Anhui Huaheng Biotechnology Co. Ltd. A (SHG:688639) — Market Cap & Net Worth
Market Cap & Net Worth: Anhui Huaheng Biotechnology Co. Ltd. A (688639)
Anhui Huaheng Biotechnology Co. Ltd. A (SHG:688639) has a market capitalization of $763.84 Million (CN¥5.22 Billion) as of June 23, 2026. Listed on the SHG stock exchange, this China-based company holds position #10274 globally and #2783 in its home market, demonstrating a 1.80% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Anhui Huaheng Biotechnology Co. Ltd. A's stock price CN¥20.87 by its total outstanding shares 250115693 (250.12 Million). Review 688639 liabilities breakdown to assess the company's total debt and financial obligations.
Anhui Huaheng Biotechnology Co. Ltd. A Market Cap History: 2021 to 2026
Anhui Huaheng Biotechnology Co. Ltd. A's market capitalization history from 2021 to 2026. Data shows growth from $2.18 Billion to $763.84 Million (5.14% CAGR).
Anhui Huaheng Biotechnology Co. Ltd. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Anhui Huaheng Biotechnology Co. Ltd. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.42x
Anhui Huaheng Biotechnology Co. Ltd. A's market cap is 0.42 times its annual revenue
Latest Price to Earnings (P/E) Ratio
9.01x
Anhui Huaheng Biotechnology Co. Ltd. A's market cap is 9.01 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $2.18 Billion | $954.10 Million | $168.24 Million | 2.28x | 12.94x |
| 2022 | $2.63 Billion | $1.42 Billion | $320.03 Million | 1.85x | 8.21x |
| 2023 | $3.11 Billion | $1.94 Billion | $449.06 Million | 1.61x | 6.93x |
| 2024 | $1.18 Billion | $2.18 Billion | $189.52 Million | 0.54x | 6.22x |
| 2025 | $1.19 Billion | $2.86 Billion | $132.41 Million | 0.42x | 9.01x |
Competitor Companies of 688639 by Market Capitalization
Companies near Anhui Huaheng Biotechnology Co. Ltd. A in the global market cap rankings as of June 23, 2026.
Key companies related to Anhui Huaheng Biotechnology Co. Ltd. A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #571 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.70 |
| #571 | Argen-X | BR:ARGX | $47.14 Billion | €773.80 |
Anhui Huaheng Biotechnology Co. Ltd. A Historical Marketcap From 2021 to 2026
Between 2021 and today, Anhui Huaheng Biotechnology Co. Ltd. A's market cap moved from $2.18 Billion to $ 763.84 Million, with a yearly change of 5.14%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥763.84 Million | -35.94% |
| 2025 | CN¥1.19 Billion | +1.15% |
| 2024 | CN¥1.18 Billion | -62.14% |
| 2023 | CN¥3.11 Billion | +18.52% |
| 2022 | CN¥2.63 Billion | +20.65% |
| 2021 | CN¥2.18 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 22nd, 2026 the market cap of Anhui Huaheng Biotechnology Co. Ltd. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $763.84 Million USD |
| MoneyControl | $763.84 Million USD |
| MarketWatch | $763.84 Million USD |
| marketcap.company | $763.84 Million USD |
| Reuters | $763.84 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Anhui Huaheng Biotechnology Co. Ltd. A
Anhui Huaheng Biotechnology Co., Ltd. engages in the research and development, production, and sale of bio-based products through bio-manufacturing in China and internationally. The company offers amino acid products, including the alanine series, L-valine, isoleucine, tryptophan, and arginine; vitamin products, such as D-calcium pantothenate, D-panthenol, and inositol; bio-based new material mon… Read more